



AN EVALUATION OF SIX MINUTE WALK TEST IN IMPROVING EXERCISE TOLERANCE IN PATIENTS OF IDIOPATHIC PULMONARY FIBROSIS

Dr. Vinit Prabhudas Niranjane

Associate Professor, Department of TB & Chest, Government Medical College & Hospital, Nagpur, Maharashtra, India

ABSTRACT:

Introduction: The six minute walk test (6MWT) is a practical and reliable measure of exercise tolerance that is used to assess the functional status of patients with many cardiac and pulmonary diseases, including heart failure, pulmonary hypertension, and chronic obstructive pulmonary disease. There is paucity of data establishing effectiveness of six minute walk test in patients with Idiopathic pulmonary fibrosis in India. In the present study we evaluated the effectiveness of six minute walk test in improving exercise tolerance and quality of life in Idiopathic pulmonary fibrosis patients

Methods: This was a Prospective study design . Subjects were randomly selected diagnosed as Idiopathic Pulmonary Fibrosis according to the American Thoracic Society Criteria, FVC greater than or equal to 55% of predicted, Diffusing capacity of carbon monoxide (DL_{CO}) greater than or equal to 35% of predicted. The 6MWT was performed at the baseline and at 18 weeks intervals.

Results: Mean (\pm SD) age at the entry of the study was 59 (\pm 13) years and 82% of the study subjects were male. The mean (\pm SD) value for 6MWD at baseline and at 18 weeks was 214 (\pm 89) m and 271 (\pm 84) respectively. There were significant variations between the study subjects in terms of dyspnoea, six minute walk distance and SGRQ scores. The 6MWT had good reliability in patients with Idiopathic pulmonary fibrosis. The intraclass Pearson's correlation coefficient for six minute walk distance between baseline and at 18 weeks was 0.6125($P < 0.05$). The patient experienced good sense of relief from the activities that required tolerance due to the improvement in six minute walk distance.

Conclusion: The six minute walk test is consistent, suitable measure of exercise tolerance in IPF patients. A MCID of 15 m is less but much appreciable since there are no related studies representing Indian patients. The six minute walk test is a clinically helpful measure of status of the disease and the mortality.

Key Word : 6MWT , Idiopathic Pulmonary Fibrosis , ATC Criteria, Borg Scale , SGRQ scores

INTRODUCTION:

Idiopathic pulmonary fibrosis (IPF) is a progressive life-threatening, interstitial lung disease of unknown etiology.¹ It is one of the most important disabling disorders of the lung and it is being increasingly recognised in India.² There is a progressive deterioration in lung function

gradually limiting routine physical activity. Idiopathic pulmonary fibrosis is one of the most common cause of idiopathic pneumonia with a median survival of only 2-5 years after diagnosis.³ The six minute walk test (6MWT) is a practical and reliable measure of exercise tolerance that is used

to assess the functional status of patients with many cardiac and pulmonary diseases, including heart failure, pulmonary hypertension, and chronic obstructive pulmonary disease (COPD).⁴⁻⁷ However, studies assessing the efficacy of the six minute walk test in south Indian patients with Idiopathic Pulmonary fibrosis have been limited.⁸ There were limited or no studies estimating the minimal clinically important difference (MCID) for the six minute walk patients in Idiopathic pulmonary fibrosis in South Indian population. The MCID is the smallest difference in the domain of interest which patients perceive as beneficial and which would mandate in the absence of troublesome side effects and excessive cost, a change in the patient's management.⁹

There is paucity of data establishing effectiveness of six minute walk test in patients with Idiopathic pulmonary fibrosis in India. In the present study we evaluated the effectiveness of six minute walk test in improving exercise tolerance and quality of life in Idiopathic pulmonary fibrosis patients

METHODOLOGY

This prospective study had a population consisted of 50 patients diagnosed as Idiopathic Pulmonary Fibrosis according to the American Thoracic Society Criteria,¹⁰⁻¹¹ FVC greater than or equal to 55% of predicted, Diffusing capacity of carbon monoxide (DL_{co}) greater than or equal to 35% of predicted. Subjects were randomly selected from patients with respiratory disorders, aged 18 years and above, and Prior Consent from the patients were taken & was found to be within ethical standards. Patients with comorbidities such as musculoskeletal disorders affecting lower limb such as Osteoarthritis, Rheumatoid arthritis and collagen disorders were excluded.

The 6MWT was performed at the baseline and at 18 weeks intervals. The test was performed indoors on a flat, straight corridor with a hard non-slippery surface. An oxygen titration procedure was performed at the baseline to evaluate a flow rate for patients who need

supplemental oxygen. Before each 6MWT, patients were required to have resting oxygen saturation as measured by finger pulse oximetry of at least 85% after 5 minutes of breathing room air. Patients were instructed to walk at their own pace and allowed to take rest periods during walking. The test was stopped if the patient experienced any chest pain, dyspnoea, leg cramps, excessive sweating, or had desaturation below 85%. Assessments of dyspnoea using rate of perceived exertion, 6MWT distance in metres, health related quality of life using St. George's Respiratory Questionnaire were also done at the baseline and at 18 weeks intervals.¹² The St George's Respiratory Questionnaire consists of three respiratory specific domains: a. Symptom, b. Activity, c. Impacts. Each domain of the questionnaire ranges from 0-100 with an advancing score indicating worsening HRQOL.¹³

Statistical Analyses

Statistical analyses were done using SPSS 18. Wilcoxon Signed rank test was used to measure the reliability of Borg Scale of Rate of Perceived Exertion and St George Respiratory Questionnaire between the baseline and at 18 weeks. The reliability of the Six Minute walk distance was measured using paired test between baseline and at 18 weeks. Criterion validity was assessed based on the relationships between six minute walk test and measures of physiologic status such as dyspnoea, St George Respiratory Questionnaire using Spearman correlation coefficients. All deaths during the 18 week period were included in the analysis. The distribution based method was used to estimate the minimally clinical important difference (MCID).

RESULTS

A total of 50 patients were selected based on the inclusion criteria. There were no drop outs during the 18 weeks period. However, some patients were readmitted for acute exacerbations and then they continued the study. Mean (\pm SD) age at the entry of the study was 59 (\pm 13) years and

82% of the study subjects were male. The mean (\pm SD) value for 6MWD at baseline and at 18 weeks was 214 (\pm 89) m and 271 (\pm 84) respectively. There were significant variations between the study subjects in terms of dyspnoea, six minute walk distance and SGRQ scores. The 6MWT had good reliability in patients with Idiopathic pulmonary fibrosis. The intraclass Pearson's correlation coefficient for six minute walk distance between baseline and at 18 weeks was 0.6125 ($P < 0.05$). The patient experienced good sense of relief from the activities that required tolerance due to the improvement in six minute walk distance.

Validity

The strong associations between the sub maximal intensity activities such as six minute walk test and measures of rate of perceived exertion (Borg Scale) and St George Respiratory questionnaire were in the desired direction. The Spearman's Correlation Coefficient between six minute walk test and Borg Scale was 0.85 which was statistically significant at $p < 0.05$. The correlation coefficient between six minute walk test and St

George Respiratory Questionnaire was 0.67 which was statistically significant at $p < 0.05$.

Correlations between changes in six minute walk test distance and changes in Borg Scale of rate of perceived exertion and quality of life were in the desired direction. There was a strong positive correlation between six minute walk test distance and Borg Scale of rate of perceived exertion and St George Respiratory Questionnaire scores. The six minute walk test distance values between baseline and at 18 weeks period values were prognostic over the subsequent 1 year period. The risk of death was more for patients with a decline in six minute walk test distance greater than 50 m according to DuBois *et al.*¹³ In our study the risk of death was more for patients with a decline in six minute walk test distance greater than 30 m.

The calculated SEM for the six minute walk test and the corresponding MCID was 15 m (95% CI). The MCID was minimal as compared to other MCIDs published in various articles. The effect size could not be measured since it was a single group quasi experimental design.

Table 1: Baseline characteristics

Characteristic	Value
Age (years) Mean (SD)	59 (\pm 13)
Gender n (%)	
Male	41(82%)
Female	09 (18%)
6MWT Distance in m Mean (SD)	214 (\pm 89) m
FVC,% predicted - Mean (SD)	68 (\pm 8)
DL _{co} ,% predicted Mean(SD)	44.3(\pm 5.6)
SGRQ Score Mean(SD)	31.33(\pm 33.4)

6MWT = 6-minute walk test; DLco= carbon monoxide diffusion capacity; SGRQ = St George Respiratory Questionnaire

Table 2: Correlation between 6mwt distance and other measures

Variable	N	Coefficient*	P value
Borg Scale	50	0.85	p<0.05
SGRQ scores	50	0.67	p< 0.05

6MWT = 6-minute walk test; capacity; SGRQ = St George Respiratory Questionnaire

*- Pearson correlation coefficient

Table 3: Estimation of the minimal clinically important difference in 6 MWT in patients with pulmonary interstitial fibrosis

Mean	SD	Correlation	SEM
6MWT distance, m 271	84	0.612	15

Definition of abbreviation: 6MWT = 6-minute walk test; capacity; SEM- standard error of measurement

*- Pearson correlation coefficient

DISCUSSION

The six minute walk test is a broadly used technique of quantifying exercise tolerance in various pulmonary disease patients. From the clinical point of view, the six minute walk test is pragmatic and has more safety. It requires only limited equipments and less training as compared to other Cardiopulmonary Exercise Testing. It is well appreciated and tolerated because the six minute walks test is self paced and resembles activities of daily living (ADL).

Based on the above advantages, the six minute walk test is a valuable assessment tool to evaluate the exercise tolerance and functional status in Idiopathic pulmonary fibrosis. Eaton *et al* found high correlations between six minute walk test distance and Vo_2 max on maximal exercise testing and predicted DL_{co} in idiopathic interstitial pneumonia.¹⁴ Caminati and coworkers postulated moderate correlations between six minute walk test distance and percent predicted FVC and percent predicted DL_{co} ($r = 0.40$ and 0.42 respectively) in a retrospective analysis of 44 patients with IPF.¹⁵ Both the researches had not shown the predictors of mortality.

In our study, we examined the reliability, validity and responsiveness of the six minute walk test and projected the MCID in small samples who performed according to the study protocol. Compared to previous studies as conducted in western countries, the distance walked during the six minute walk test was well reproducible, representing good reliability but the sample size was small. The relationship between 18 week changes in six minute walk distance and the risk of 1 year mortality was good and said to be greatly responsiveness. The risk of death was more for patients with a decline in six minute walk test distance greater than 30 m. This is an extremely important measure of prognosis for IPF patients. The minimal clinically important differences for our patients were 15 m and it was less as compared to Roland *et al* studies and Redelmeier *et al* studies in COPD.¹⁶ The results were as close to 29 m reported by Holland *et al*.¹⁷ Till date there was no published data for MCID for six minute walk test in South Indian IPF patients and so we could not compare the data. However, the patient experienced a sense of well being after 18 weeks and it was evident in quality of life scores and improvement in six minute walk distance. There

are some limitations in our study such as there was no control group and the sample size was small.

CONCLUSION

The six minute walk test is consistent, suitable measure of exercise tolerance in IPF patients. A MCID of 15 m is less but much appreciable since there are no related studies representing Indian patients. The six minute walk test is a clinically helpful measure of status of the disease and the mortality.

ACKNOWLEDGEMENTS

We would like to thank all the Participating patients, Our Head of Department for his always available guidance.

Compliance with Ethical Standards

Conflict Of Interest – None.

Funding – None.

Informed Consent Obtained.

REFERENCES

1. Du Bois RM, Weycker D *et al.* Six minute walk test in Idiopathic pulmonary fibrosis Test validation and minimal clinically important difference. *Am J Respir Crit Care Med* 2011; 183:1231-7.
2. Subhash H S, Ashwin I, Solomon SK, David T, Cherian AM. A comparative study on Idiopathic pulmonary fibrosis and secondary diffuse parenchymal lung disease. *Indian J Med Sci* 2004;58: 185-90.
3. Latsi PI, du Bois RM, Micholson AG, *et al.* Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. *Am J Respir Crit Care Med* 2003; 168:531- 7.
4. Lipkin DP, Scriven AJ, Crake T, Poole-Wilson. Six minute walking test for assessing exercise capacity in chronic heart failure. *Br Med J* 1986; 292: 653-5.
5. Cahalin LP, Mathier MA, Semigran MJ *et al.* the six minute walk test predicts peak oxygen uptake and survival in patients with heart failure. *Chest* 1996;110:325-32.
6. Gomberg-Maitland M, Huo D *et al.* Creation of a model comparing 6 minute walk test to metabolic equivalent in evaluating treatment effects in pulmonary arterial hypertension. *J Heart Lung Transplant* 2007;26: 732-8.
7. Guyatt GH, Pugsley SQ *et al.* Effect of encouragement on walking test performance. *Thorax* 1984; 39:818-22.
8. Baughman RP, Sparkman BK, Lower EE. Six minute walk test and health assessment in sarcoidosis. *Chest* 2007;132:207-13.
9. Jasechke R, Singer J, Guyatt GH. Measurement of health status, ascertaining the minimal clinically important difference. *Control Clin Trials* 1989;10:407-15.
10. American Thoracic Society, European Respiratory Society, Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. *Am J Respir Crit Care Med* 2000; 161:646-64.
11. American Thoracic Society, European Respiratory Society, ATS/ERS International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2002; 166: 277-304.
12. American Thoracic society statement: Guidelines for the six minute walk test. *Am J Respir Crit Care Med* 2002;166: 111-7.
13. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of health related quality of life in patients with interstitial lung disease. *Chest* 1999; 116:1175-82.
14. Eaton T, Young P, Milne D, Wells AU. Six minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. *Am J Respir Crit Care Med* 2005; 171: 1150-7.
15. Caminati A, Bianchi A, *et al.* Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. *Respir Med* 2009; 103:117- 23.
16. Redelmeier DA, Bayoumi AM, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in chronic lung disease patients. *Am J Respir Crit Care Med* 1997;155: 1278-2.

17. Holland AE, Hill CJ, Conron M, Munro P et al. Small changes in six minute walk distance are important in diffuse parenchymal lung disease. *Respir Med* 2009; 103:1430-5